ReviewCurrent allergy and asthma reports2026
A Review of Adenosine Deaminase 2 (ADA2) as a Biomarker of Monocyte/Macrophage Activation.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAdenosine deaminase 2 (ADA2) is predominantly expressed by and secreted from activated monocytes and macrophages into plasma. This review explores the utility of ADA2 as a biomarker of monocyte/macrophage activation in a range of conditions and suggests potential applications for its clinical use. RECENT
findingsElevated ADA2 activity has been observed in conditions associated with granulomatous inflammation and macrophage activation, including tuberculosis, sarcoidosis, and macrophage activation syndrome. This finding has also been reported in liver fibrosis, malignancy, infection, and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Absent or near absent ADA2 activity is associated with deficiency of ADA2 (DADA2), an autosomal recessive inborn error of immunity. Increased ADA2 activity correlates with monocyte/macrophage activity, making it a potential biomarker in diseases characterized by excessive macrophage activation. Although ADA2 activity is relatively easy to measure in plasma and may assist with diagnosis when conventional approaches are unavailable, invasive, or carry additional risks, it lacks disease specificity. The absence of ADA2 activity in plasma combined with a characteristic clinical phenotype and biallelic genetic mutations inADA2 is diagnostic of DADA2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.